Overview

• Patients in the Phase III REDEFINE 1 trial lost an average of 20.4% of their body weight on CagriSema over 68 weeks, below Novo Nordisk’s 25% goal, with mostly mild-to-moderate gastrointestinal side effects.
• Wegovy will be offered in five injectable dose strengths at an estimated ₹14,000 per month to undercut Lilly’s Mounjaro, which costs about ₹17,000 per month.
• Since its March 2025 debut, Mounjaro has recorded sales of roughly ₹24 crore in India and tripled consumption as doctors and patients embrace its dual GIP and GLP-1 mechanism.
• Novo Nordisk is advancing other pipeline candidates, including amycretin, which is entering Phase III in oral and subcutaneous forms after showing up to 24.3% weight loss in early trials.
• With semaglutide patents expiring in March 2026, Indian firms such as Dr. Reddy’s, Sun Pharma, Cipla, Natco and Zydus Lifesciences are gearing up to launch generic semaglutide alternatives.